menu
    • menu

    Company profile for Celyad Oncology

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Celyad Oncology is a biotechnology company focused on the discovery and development of innovative technologies for chimeric antigen receptor (CAR) T-cell therapies. The Company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T-cell candidates in solid tumors and hematological malignancies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Celyad OncologyBelgium Flag
    Country
    Country
    Belgium
    Address
    Address
    Axis Business Park Rue Edouard Belin 2 1435 Mont-Saint-Guibert
    Telephone
    Telephone
    +32 010394100
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://celyad.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/celyadoncology/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/CelyadSA

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Celyad Oncology Gets Transparency Notice from Fortress Group
    Celyad Oncology Gets Transparency Notice from Fortress Group

    11 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-11/celyad-oncology-sa-publication-of-a-transparency-notification-received-from-fortress-investment-gro

    PHARMAWEB
    11 Sep 2025
    Share Share
    Celyad Oncology SA Discloses Voting Rights and Shares Data
    Celyad Oncology SA Discloses Voting Rights and Shares Data

    04 Sep 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-09-04/celyad-oncology-sa-information-on-the-total-number-of-voting-rights-and-shares-article-15-of-the-l

    PHARMAWEB
    04 Sep 2025
    Share Share
    Celyad Oncology Announces Discontinuation of R&D Activities
    Celyad Oncology Announces Discontinuation of R&D Activities

    26 Aug 2025

    // PHARMAWEB

    https://www.pharmiweb.com/press-release/2025-08-26/celyad-oncology-announces-discontinuation-of-rd-activities

    PHARMAWEB
    26 Aug 2025
    Share Share
    Celyad Oncology announces intention to terminate SEC reporting obligations
    Celyad Oncology announces intention to terminate SEC reporting obligations

    08 Feb 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/02/08/2826424/0/en/Celyad-Oncology-announces-intention-to-terminate-SEC-reporting-obligations.html

    GLOBENEWSWIRE
    08 Feb 2024
    Share Share
    Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook
    Celyad Oncology provides fourth quarter 2023 business update and 2024 outlook

    16 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/16/2810297/0/en/Celyad-Oncology-provides-fourth-quarter-2023-business-update-and-2024-outlook.html

    GLOBENEWSWIRE
    16 Jan 2024
    Share Share
    Publication of transparency notification received from Fortress Investment Group
    Publication of transparency notification received from Fortress Investment Group

    20 Dec 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/12/20/2799636/0/en/Publication-of-a-transparency-notification-received-from-Fortress-Investment-Group-LLC-Article-14-1-of-the-Law-of-2-May-2007.html

    GLOBENEWSWIRE
    20 Dec 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search